KINDSTAR GLOBAL announced its interim results, with a gross profit of 197 million yuan, as all business segments achieved stable progress

According to the Zhitong Finance APP, KINDSTAR GLOBAL (09960) released its interim results for the six months ending June 30, 2025, with revenue of 457 million yuan (RMB, the same below); gross profit of 197 million yuan; and R&D costs of 46.046 million yuan. The announcement stated that in the first half of 2025, the overall cooperation hospitals for hematology testing services maintained steady growth, with over 90 new hospital clients added. The group's pediatric hematology sector continued to establish itself in children's oncology specialty hospitals and large tertiary hospitals' pediatric hematology departments, adding 48 new cooperative hospitals in the first half of 2025. The sales of its NGS testing IG/TCR rearrangement technology products increased by over 50% during the reporting period, reflecting its core technological advantages and product characteristics. In the neurology field, while the group's testing projects have covered almost all neurological diseases, it continued to delve into market demand, adding 34 new testing projects and 44 new cooperative testing hospitals in the first half of the year, further deepening cooperation projects with Southern Hospital. In terms of pharmaceutical company collaboration, the neurology business line implanted its own special testing projects in multi-center studies, proactively preparing for the future blood testing opportunities in neurodegenerative diseases. Adhering to innovation-driven development is fundamental for the group in establishing itself in the industry. In the first half of 2025, the group's research and development department published 33 articles, applied for 67 patents, of which 29 were authorized, and obtained 24 copyrights. During the reporting period, the group added a total of 56 new R&D testing projects, including 16 related to molecular biology testing technology, 16 related to flow cytometry testing technology, 7 related to cytogenetic testing technology, and 6 related to pathological testing technology. In the first half of 2025, the group's core product in the immune repertoire, the Linsikang business applied to minimal residual disease detection in hematological tumors, further expanded, covering over 160 institutions across 26 provinces, with revenue increasing nearly 30% compared to the same period in 2024. In 2024, KINDSTAR GLOBAL's subsidiary, KINDSTAR BEITAI, achieved a perfect score in the EuroClonality EQA program for its Ig/TCR project, becoming the only laboratory in the country to participate and achieve a perfect score, marking a key step towards internationalization in the field of immune repertoire testing in China